title: Transcervical cannulation of the fallopian tube for the management of ectopic pregnancy: prospective multicenter study.
abstract: OBJECTIVE
  To determine the efficacy of transcervical tubal cannulation and intraluminal methotrexate injection for the management of tubal ectopic pregnancy (EP).
  
  
  METHODS
  Prospective multicenter study of 33 patients with tubal pregnancies.
  
  
  METHODS
  Four university-based gynecology and radiology departments in three different countries: France, England, and Germany.
  
  
  METHODS
  Thirty-three patients who presented with a clinical diagnosis of EP.
  
  
  METHODS
  Patients underwent transcervical tubal cannulation under fluoroscopic or ultrasound control and local injection of methotrexate (up to 50 mg).
  
  
  METHODS
  We evaluate the feasibility of transcervical tubal cannulation for the management of tubal pregnancy.
  
  
  RESULTS
  Two patients elected to withdraw from the protocol. In the remaining 31 patients there was complete resolution of the EP in 27 (87%). Surgery was performed in 4 patients. Seventeen patients, 14 of whom desired pregnancies, were available for follow-up to assess the return of reproductive potential. Seven of 7 patients who subsequently underwent hysterosalpingography had patency of the affected tube. Five patients later had an intrauterine pregnancy. One patient had an early miscarriage, two have given birth, and two singleton pregnancies are still ongoing. The remaining patients are symptom free.
  
  
  CONCLUSIONS
  This study demonstrates that transcervical tubal catheterization in patients with tubal pregnancies is feasible and can be performed without anesthesia or analgesia in most cases. Intraluminal methotrexate per se is capable of causing regression of the EP. This approach offers a new alternative for the treatment of selected patients with tubal EP.
authors.affiliation: Clinique Universitaire Baudelocque, Hôpital Cochin, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Rísquez
authors.forename: R
authors.initials: R
authors.lastname: Forman
authors.forename: F
authors.initials: F
authors.lastname: Maleika
authors.forename: H
authors.initials: H
authors.lastname: Foulot
authors.forename: J
authors.initials: J
authors.lastname: Reidy
authors.forename: M
authors.initials: M
authors.lastname: Chapman
authors.forename: J R
authors.initials: JR
authors.lastname: Zorn
mesh_terms: D000328:Adult; D002404:Catheterization; D002584:Cervix Uteri; D006063:Chorionic Gonadotropin / Q000097:blood; D005187:Fallopian Tubes; D005260:Female; D005865:Gestational Age; D006801:Humans; D007047:Hysterosalpingography; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000628:therapy*; D011446:Prospective Studies; D014463:Ultrasonography
chemical_list: D006063:Chorionic Gonadotropin; D008727:Methotrexate